CDX-301

DB19293InvestigationalProtein Based Therapies

CDX-301 is under investigation in clinical trial NCT02129075 (A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma).

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3
Curator reviewed
Code names: AMG-949 · CDX-301

Resolves to

Compound

UNIISP24YIT5YZ

Targets

P36888FLT3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with CDX-301, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account